19-Nor-C3,3-Disubstituiertes C21-N-Pyrazolylsteroid zur Verwendung bei der Behandlung Schwerer Depressionen und Postpartum-Depressionen

Details

Veröffentlichungs-Nr.

EP4768044

Anmeldetag

29. April 2022

Veröffentlichung

1. Juli 2026

Rechtsraum

EP

IPC

A61K45/06

Abstract

The present disclosure relates to methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, by administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof. The disclosure also relates to methods of treating postpartum depression (PPD) with elevated anxiety in a subject in need thereof, by administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof.

Anmelder

Firma

Sage Therapeutics, LLC

Land

🇺🇸 USA